ASCO, page-10

Guys .... there is a good chance this report is already available.  This was what Dr Graham said on May 3.  

Those 14 patients then moved on to a higher dose of carboplatin. This next dose of carboplatin is still short of the standard dose -- it's now three-quarters of the standard dose -- but it's dose high enough where we would expect to start to see side-effects, and the whole idea is to see how far we can push up that dose of carboplatin and still get a protective effect from NOX66.

That study is now completed, and the results are being collated and analysed, and the results have been accepted for presentation at ASCO, which is the largest cancer research conference in the world. It's in Chicago in the first week of June.

http://www.finnewsnetwork.com.au/MediaCenter/MediaCenterMobile.aspx?Site=FNN1230


I doubt they will still be collecting data. Analysing, maybe but you are nearing the ASCO presentation so surely you want to be prepared making the presentation.